Kapstone Financial Advisors LLC Takes $292,000 Position in Eli Lilly and Company (NYSE:LLY)

Kapstone Financial Advisors LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 465 shares of the company’s stock, valued at approximately $292,000.

Other hedge funds have also recently modified their holdings of the company. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $27,000. Legacy Financial Group LLC purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $36,000. Finally, Family CFO Inc purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $40,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on LLY shares. Truist Financial restated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $728.05.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $8.64 during mid-day trading on Friday, hitting $733.51. 2,009,249 shares of the company’s stock traded hands, compared to its average volume of 2,265,427. The company’s 50-day moving average is $761.79 and its two-hundred day moving average is $666.67. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company has a market capitalization of $696.95 billion, a P/E ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $380.77 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.09 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.